Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM)

NCT06574126 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT06574126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06574126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM)
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2024
Completion date
September 30, 2032
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk smoldering multiple myeloma